Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/6125
Full metadata record
DC FieldValueLanguage
dc.contributor.authorInstituto Nacional de Câncer José Alencar Gomes da Silva-
dc.contributor.authorInstituto Nacional de Câncer (Brasil)-
dc.contributor.authorINCA-
dc.contributor.authorBrasil. Ministério da Saúde-
dc.contributor.authorSistema Único de Saúde (Brasil)-
dc.date.accessioned2022-03-30T13:14:03Z-
dc.date.available2022-03-30T13:14:03Z-
dc.date.issued2022-03-
dc.identifier.urihttp://sr-vmlxaph03:8080/jspui/handle/123456789/6125-
dc.description2 p.-
dc.language.isootherpt_BR
dc.publisherINCApt_BR
dc.relation.ispartofseriesAno VI, n. 58.-
dc.subjectAntineoplásicospt_BR
dc.subjectAntineoplastic Agentspt_BR
dc.subjectOncologiapt_BR
dc.subjectMedical Oncologypt_BR
dc.subjectOncología Médicapt_BR
dc.subjectTratamento Farmacológicopt_BR
dc.subjectDrug Therapypt_BR
dc.subjectQuimioterapiapt_BR
dc.titleQuimioterapia de finalidade paliativapt_BR
dc.TypeRevista/Boletimpt_BR
Appears in Collections:Informe SUS - ONCO 2022

Files in This Item:
File Description SizeFormat 
Março_2022_2.pdf481.91 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.